EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Peptide Drug Conjugates and Their Role in Cancer Therapy

Ethan Heh iD, Jesse Allen iD, Fabiola Ramirez iD, Daniel Lovasz iD, Lorena Fernandez iD, Tanis Hogg, Hannah Riva, Nathan Holland iD, Jessica Chacon iD

International Journal of Molecular Sciences · 03.01.2023 · 24 (1) · 829

DOI: 10.3390/ijms24010829 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.01.2023. Verfasst von Ethan Heh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Paul L. Foster School of Medicine, Department of Medical Education, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Immunoconjugates, Cell-Penetrating Peptides. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug conjugates have become a significant focus of research in the field of targeted medicine for cancer treatments. Peptide-drug conjugates (PDCs), a subset of drug conjugates, are composed of carrier peptides ranging from 5 to 30 amino acid residues, toxic payloads, and linkers that connect the payload to the peptide. PDCs are further broken down into cell-penetrating peptides (CPPs) and cell-targeting peptides (CTPs), each having their own differences in the delivery of cytotoxic payloads. Generally, PDCs as compared to other drug conjugates—like antibody-drug conjugates (ADCs)—have advantages in tumor penetration, ease of synthesis and cost, and reduced off-target effects. Further, as compared to traditional cancer treatments (e.g., chemotherapy and radiation), PDCs have higher specificity for the target cancer with generally less toxic side effects in smaller doses. However, PDCs can have disadvantages such as poor stability and rapid renal clearance due to their smaller size and limited oral bioavailability due to digestion of its peptide structure. Some of these challenges can be overcome with modifications, and despite drawbacks, the intrinsic small size of PDCs with high target specificity still makes them an attractive area of research for cancer treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsImmunoconjugatesCell-Penetrating PeptidesHumansPharmaceutical PreparationsAntibodies, MonoclonalAntigens

Stichwörter der Autor:innen

bioconjugatescarrierlinkerpayloadpeptide-drug conjugates

Substanzen

Pharmaceutical PreparationsAntibodies, MonoclonalAntineoplastic AgentsImmunoconjugatesCell-Penetrating PeptidesAntigens

Autor:innen und Institutionen

  • Paul L. Foster School of Medicine, Department of Medical Education, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA.

ORCID-Profile: Ethan Heh, Jesse Allen, Fabiola Ramirez, Daniel Lovasz, Lorena Fernandez, Nathan Holland, Jessica Chacon

Zitieren

APA

Heh, E., Allen, J., Ramirez, F., Lovasz, D., Fernandez, L., Hogg, T., Riva, H., Holland, N., & Chacon, J. (2023). Peptide Drug Conjugates and Their Role in Cancer Therapy. International Journal of Molecular Sciences, 24(1), 829. https://doi.org/10.3390/ijms24010829

Vancouver

Heh E, Allen J, Ramirez F, Lovasz D, Fernandez L, Hogg T, et al. Peptide Drug Conjugates and Their Role in Cancer Therapy. International Journal of Molecular Sciences. 2023;24(1):829. doi:10.3390/ijms24010829

BibTeX
@article{Heh2023,
  author = {Heh, Ethan and Allen, Jesse and Ramirez, Fabiola and Lovasz, Daniel and Fernandez, Lorena and Hogg, Tanis and Riva, Hannah and Holland, Nathan and Chacon, Jessica},
  title = {Peptide Drug Conjugates and Their Role in Cancer Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {1},
  pages = {829},
  doi = {10.3390/ijms24010829}
}
Kostenlos starten →